Physician profile
Emily Carnes
NPI 1578170189
$1,931.78
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $771 · 2022: $461 · 2023: $419 · 2024: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $743.04 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $216.07 | 2021-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $161.21 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $123.78 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $120.67 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $119.81 | 2021-2022 | |
| Harmony Biosciences LLC | $77.76 | 2024 | |
| Amgen INC. | $52.66 | 2021-2023 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $44.22 | 2024 | Sunosi |
| Inspire Medical Systems, INC. | $40.79 | 2024 | Inspire |
| Astellas Pharma US INC | $36.67 | 2023-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $35.68 | 2021 | |
| Lilly USA, LLC | $34.68 | 2022-2023 | Mounjaro |
| Abbvie INC. | $29.45 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.29 | 2023 | Synjardy, Jardiance, Tradjenta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21.31 | 2024 | |
| Pfizer INC. | $18.96 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.19 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $15.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Carnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.